ArticleVaccines2020
A Pool of Eight Virally Vectored African Swine Fever Antigens Protect Pigs Against Fatal Disease.
Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.
- Quantitative evaluation of the efficacy of non-replicating vaccines for controlling African swine fever in domestic pigs: a systematic review and meta-analysis.Frontiers in veterinary science · 2025Pooled it
- Limited cross-protection induced by live attenuated ASF vaccines emphasizes caution for field use.Emerging microbes & infections · 2026Article
- Current Insights into the Epidemiology and Transmission Dynamics of African Swine Fever Virus and Future Control Perspectives.Pathogens (Basel, Switzerland) · 2026Review
- Advances in African swine fever vaccine development: challenges and prospects.Journal of veterinary science · 2026Review
- African swine fever virus genes vectored by simian adenoviruses do not protect against virulent genotype II virus challenge.Microbiology spectrum · 2026Article
- Characterization of African swine fever outbreaks in Hong Kong SAR, winter 2023 to 2024.Microbiology spectrum · 2026Article
- The Prospects and Challenges of Live Attenuated Vaccines Against African Swine Fever Virus in Vietnam.Vaccines · 2026Review
- Virus-like and Virus Replicon Particles Targeting Multiple B-Cell Antigens Do Not Protect Against African Swine Fever Virus.Vaccines · 2026Article
- African Swine Fever: Vaccine Advancement and Major Gaps.Microorganisms · 2026Review
- Oral Bait Immunization of Eurasian Wild Boar (Vaccines · 2026Article
- Live-vectored antigen cocktail confers protection against African swine fever virus (ASFV) Georgia 2007/1 challenge.NPJ vaccines · 2026Article
- Recombinant vaccinia vectored ASFV vaccine enhances swine survival against genotype II challenge.NPJ vaccines · 2026Article
- Article
- Implications for safety:Frontiers in microbiology · 2026Article
- ASFV Proteins Presented at the Surface of T7 Phages Induce Strong Antibody Responses and Immune Cell Proliferation inVaccines · 2025Article
- An attenuated African swine fever virus expressing the E2 glycoprotein of classical swine fever virus protects pigs against challenge of both viruses.Emerging microbes & infections · 2025Article
- The p15 protein is a promising immunogen for developing protective immunity against African swine fever virus.Protein & cell · 2025Article
- Article
- An African swine fever virus-specific antibody reactome reveals antigens as potential candidates for vaccine development.Journal of virology · 2025Article
- Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
Classical approaches to African swine fever virus (ASFV) vaccine development have not been successful; inactivated virus does not provide protection and use of live attenuated viruses generated by passage in tissue culture had a poor safety profile. Current African swine fever (ASF) vaccine research focuses on the development of modified live viruses by targeted gene deletion or subunit vaccines. The latter approach would be differentiation of vaccinated from infected animals (DIVA)-compliant, but information on which viral proteins to include in a subunit vaccine is lacking. Our previous work used DNA-prime/vaccinia-virus boost to screen 40 ASFV genes for immunogenicity, however this immunization regime did not protect animals after challenge. Here we describe the induction of both antigen and ASFV-specific antibody and cellular immune responses by different viral-vectored pools of antigens selected based on their immunogenicity in pigs. Immunization with one of these pools, comprising eight viral-vectored ASFV genes, protected 100% of pigs from fatal disease after challenge with a normally lethal dose of virulent ASFV. This data provide the basis for the further development of a subunit vaccine against this devastating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.